
The vaccine was developed in collaboration with several research centers. It is planned to launch it in general circulation in early 2025.
Earlier, Director of the Gamaleya National Research Center for Epidemiology and Microbiology Alexander Gintsburg told TASS that the vaccine's pre-clinical trials had shown that it suppresses tumor development and potential metastases.
Source link